Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
About this trial
This is an interventional treatment trial for Atypical Endometrial Hyperplasia focused on measuring Endometrial Carcinoma, Atypical Endometrial Hyperplasia
Eligibility Criteria
Inclusion Criteria: Have a confirmed pathological diagnosis based upon hysteroscopy: histologically prove AEH or well-differentiated EEC G1 without myometrial invasion: 1. Untreated patients; 2. Patients with persistent lesions after one course (12 weeks) of progesterone therapy; 3. Patients who did not achieve complete remission after 2 courses (24 weeks) of progesterone therapy; No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound Have a desire for remaining reproductive function or uterus Good compliance with adjunctive treatment and follow-up Exclusion Criteria: Hypersensitivity or contradiction for using MPA or atorvastatin Pregnancy or potential pregnancy Confirmed diagnosis of any cancer in reproductive system Already diagnosed with hyperlipidemia and using lipid-lowering drugs Acute liver disease or liver tumor (benign or malignant) or renal dysfunction Acute severe disease such as stroke or heart infarction or a history of thrombosis disease With other factors of reproductive dysfunction; Strong request for uterine removal or other conservative treatment Smoker (>15 cigarettes a day) Drinker (>20 grams a day)
Sites / Locations
- Wang JianliuRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Experimental group
Control groups
MPA + Atorvastatin
MPA